In the pharmacological research and drug discovery of psychiatric disorders, we provide a series of efficient technical platforms to better understand psychosis, including Omics Tools, Imaging Techniques and Behavior Tests.

The entry and distribution rate of drugs and endogenous substances in the mammalian central nervous system (CNS) depends on the special anatomical structure of the blood-brain and blood-cerebrospinal fluid barrier, the physical and chemical properties of the substance or the drug. We are capable of systematic analysis of CNS transport.

Innovation is essential to identify novel pharmacological therapies to meet the treatment needs of patients with psychiatric disorders. We link pharmacodynamic markers with disease biology to provide more predictive and innovative early clinical trials, which will increase the success rate of discovering new drugs.

The existing pharmacological methods for psychiatric disorders are not ideal, and there is much scope for the development of novel compounds that may be related to improved effectiveness and acceptability in clinical practice. We firmly grasp this opportunity to develop drugs for various targets related to psychosis, and promote the research on their treatment.

Because of its multifactorial origins, high heterogeneity and symptoms, such as hallucinations and delusions, it is difficult to evaluate psychiatric disorders in an experimental animal model. Therefore, we not only provide a variety of methods to construct animal models, but also provide cell-based in vitro models.

Target validation ensures that target participation has potential therapeutic benefits; as with target identification, it is a key step in drug development. We provide a portfolio assessment tool to help assess confidence in the drug development process.